Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

4.89%

$1.07 mesoblast limited

Thanks for the thoughtful post Yankee. Looking at the yearly...

First 4 Last

Share
Profile

Follow
roka

1,379 Posts.

281

13/02/17

21:56

Post #: 22582220
Share

Originally posted by The Yankee ↑

Comparing the Aug 09, 2016 Phase 2 RA trial results with today's Ann:
1. The 08/09/2016 trial results were (obviously) in humans but the primary objective of that was to evaluate safety and tolerability of MPC-300-IV.
a) safety was established - meaning no serious adverse affects
b) Tolerability - was well tolerated after intravenous injection of the stem cells
2. The other objective was to measure effectiveness. Which was done by
a) Improvement in ACR 70, ACR 50 and ACR 20 (these are the patients' assessments)
b) Improvements were shown in swollen joint counts, investigator global assessment, patient global assessment, and
patient pain scores.

As we can see, most everything fro the human study was based on improvement in pain and function. There were no objective measurements within the human anatomy/biology itself.

So what about the study on sheep??
Here are the main things to be noted:
a) Its showed objective improvements by way of reduced joint cartilage erosions, and improved synovial inflammation and histopathology
The important thing to note here is that cartilage erosion, synovial inflammation and histopathology were NOT evaluated in the human trial.
b) STRO-1 positive MPCs have been shown to be at least 10- fold more potent inhibitors of T-cell activation and proliferation than conventional plastic-adherent Mesenchymal Stem Cells (MSCs)
c) The study in sheep provides translational and mechanistic support to the trial in humans.

So what the heck does "translational and mechanistic support" mean?
Translational means scientific discoveries are moved along a virtual path from the laboratory into real-world practice, leading to improved human health.
Mecahanistic means that which explains the mechanism of action (in this case, how the stem cells are acting physically to improve the cartilage, synovial fluids, etc.)

My take:
1. Using STRO-1 postive MPCs is 10 times more potent
2. Mesoblast's MPCs for RA is clearly showing measurable improvement in cartilage erosion, synovial inflammation and histopathology - something that wasn't done in the human trial yet
3. The super awesome results in sheep provide support to the human trial in that humans too could show these objective, measurable improvements (though that is something that needs to be demonstrated in humans of course).

Awesome, awesome results!!

Expand

Thanks for the thoughtful post Yankee.
Looking at the yearly chart MSB is still scraping along the bottom.
Once the market sees an avenue to market, rather than trial results, we'll see liftoff.
This particular trial result gives greater confidence in the drug.
Sheep model has high fidelity for humans.
Study only went for two weeks, showed really good results, but are the effects sustained over a long time period?
Translating to humans could show a short strong response, but then what?
I would have though it would be easy to examine the Sheep a few months later.
Human trials will be over a decent time period.

Last edited by roka: 13/02/17

MSB Price at posting: $1.54 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

PAM

PAM secures high-grade Chilean copper play in strong territory

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

There are more pages in this discussion • 6 more messages in this thread...

First 4 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.07		Change -0.055(4.89%)		Mkt cap ! $1.221B

Open	High	Low	Value	Volume
$1.14	$1.16	$1.06	$8.816M	8.055M

Buyers (Bids)

No.	Vol.	Price($)
1	280000	$1.07

Sellers (Offers)

Price($)	Vol.	No.
$1.07	2000	1

View Market Depth

No.	Vol.	Price($)
1	280000	1.065
5	149799	1.060
9	124023	1.055
14	191984	1.050
8	134232	1.045

Price($)	Vol.	No.
1.070	2000	1
1.075	19000	2
1.080	48905	3
1.085	28905	1
1.090	61845	5

Last trade - 16.10pm 29/07/2024 (20 minute delay)

MSB (ASX) Chart

Thanks for the thoughtful post Yankee. Looking at the yearly...

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for the thoughtful post Yankee. Looking at the yearly...

Top Stories

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News